FIBRINOLYTIC THERAPY MARKET ANALYSIS

Fibrinolytic Therapy Market By Drug Type (Alteplase, Reteplase, Tenecteplase, Streptokinase, Anistreplase,Urokinase), By Indication (Acute Ischemic Stroke, Acute Myocardial Infarction, Deep Vein Thrombosis, Pulmonary Embolism, Peripheral Arterial Thrombosis, Other Thrombotic Conditions), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others), By Administration (Intravenous (IV), Intra-arterial (IA)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Patient Age (Adult Patients, Pediatric Patients), By Packaging Type (Vials, Ampoules, Pre-filled Syringes), By Application (Emergency Care, Interventional Cardiology, Thrombosis Treatment, Others), By Dosage Form (Lyophilized Powder for Reconstitution, Solution for Injection), By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Recent Developments

Research and Development

Genentech, Inc., a biotechnology company, in collaboration with Memorial Healthcare System, a provider of healthcare services, initiated study in June 2021, of Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis versus Standard of care Talc therapy in patients with recurrent pleural effusion. The study is expected to get ccompleted by December 2024.
In December 2021, Grand Pharma (China) Co., Ltd., a pharmaceutical company, initiated research study to evaluate the safety and efficacy of tirofiban in combination with intravenous thrombolytic therapy with alteplase in acute ischemic stroke.